{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:59:12Z","timestamp":1788238752891,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s00228-023-03461-z","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T20:37:31Z","timestamp":1676061451000},"page":"445-460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1007","volume":"79","author":[{"given":"Adriana F. S.","family":"Fontes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando M.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L\u00facia","family":"C\u00e2ndido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6870-2063","authenticated-orcid":false,"given":"Karina B.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica A. G.","family":"Tosatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"3461_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1687-9856-2011-9","volume":"1","author":"DH Geller","year":"2011","unstructured":"Geller DH, Pacaud D, Gordon CM, Misra M (2011) of the Drug and Therapeutics Committee of the Pediatric Endocrine Society (2011) State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol 1:9. https:\/\/doi.org\/10.1186\/1687-9856-2011-9","journal-title":"Int J Pediatr Endocrinol"},{"issue":"1","key":"3461_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19(1):41\u201347. https:\/\/doi.org\/10.1093\/humrep\/deh098","journal-title":"Hum Reprod"},{"issue":"1","key":"3461_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","volume":"106","author":"D Lizneva","year":"2016","unstructured":"Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R (2016) Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 106(1):6\u201315. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.05.003","journal-title":"Fertil Steril"},{"key":"3461_CR4","doi-asserted-by":"publisher","unstructured":"Rocha AL, Oliveira FR, Azevedo RC et al (2019) Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res 8:F1000 Faculty Rev-565. Published 2019 Apr 26. https:\/\/doi.org\/10.12688\/f1000research.15318.1","DOI":"10.12688\/f1000research.15318.1"},{"issue":"Suppl 6","key":"3461_CR5","doi-asserted-by":"publisher","first-page":"s72","DOI":"10.7861\/clinmedicine.15-6-s72","volume":"15","author":"TM Barber","year":"2015","unstructured":"Barber TM, Dimitriadis GK, Andreou A, Franks S (2015) Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. Clin Med (Lond) 15(Suppl 6):s72\u2013s76. https:\/\/doi.org\/10.7861\/clinmedicine.15-6-s72","journal-title":"Clin Med (Lond)"},{"issue":"1\u20133","key":"3461_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jsbmb.2009.12.010","volume":"122","author":"CG Baptiste","year":"2010","unstructured":"Baptiste CG, Battista MC, Trottier A, Baillargeon JP (2010) Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol 122(1\u20133):42\u201352. https:\/\/doi.org\/10.1016\/j.jsbmb.2009.12.010","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"3461_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3109\/09513590.2014.887063","volume":"30","author":"D Kocer","year":"2014","unstructured":"Kocer D, Bayram F, Diri H (2014) The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol 30(5):367\u2013371. https:\/\/doi.org\/10.3109\/09513590.2014.887063","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"3461_CR8","first-page":"187","volume":"8","author":"R Dumitrescu","year":"2015","unstructured":"Dumitrescu R, Mehedintu C, Briceag I, Purc\u0103rea VL, Hudita D (2015) Metformin-clinical pharmacology in PCOs. J Med Life 8(2):187\u2013192","journal-title":"J Med Life"},{"key":"3461_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejogrb.2022.01.025","volume":"271","author":"R Magzoub","year":"2022","unstructured":"Magzoub R, Kheirelseid EAH, Perks C, Lewis S (2022) Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. Eur J Obstet Gynecol Reprod Biol 271:38\u201362. https:\/\/doi.org\/10.1016\/j.ejogrb.2022.01.025","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"3461_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09513590.2022.2136160","volume":"26","author":"A Unanyan","year":"2022","unstructured":"Unanyan A, Pyvazian L, Krylova E et al (2022) Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis. Gynecol Endocrinol 26:1\u201312. https:\/\/doi.org\/10.1080\/09513590.2022.2136160","journal-title":"Gynecol Endocrinol"},{"issue":"5","key":"3461_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/01.atv.6.5.495","volume":"6","author":"AL Lin","year":"1986","unstructured":"Lin AL, Gonzalez R Jr, Carey KD, Shain SA (1986) Estradiol-17 beta affects estrogen receptor distribution and elevates progesterone receptor content in baboon aorta. Arteriosclerosis 6(5):495\u2013504. https:\/\/doi.org\/10.1161\/01.atv.6.5.495","journal-title":"Arteriosclerosis"},{"issue":"5","key":"3461_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/09513590.2015.1006188","volume":"31","author":"MG Kaya","year":"2015","unstructured":"Kaya MG, Yildirim S, Calapkorur B, Akpek M, Unluhizarci K, Kelestimur F (2015) Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecol Endocrinol 31(5):401\u2013405. https:\/\/doi.org\/10.3109\/09513590.2015.1006188","journal-title":"Gynecol Endocrinol"},{"key":"3461_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.pharmthera.2018.07.007","volume":"192","author":"A Nafisa","year":"2018","unstructured":"Nafisa A, Gray SG, Cao Y et al (2018) Endothelial function and dysfunction: impact of metformin. Pharmacol Ther 192:150\u2013162. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.07.007","journal-title":"Pharmacol Ther"},{"issue":"6","key":"3461_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/00365513.2019.1637535","volume":"79","author":"K Wyskida","year":"2019","unstructured":"Wyskida K, Franik G, Pohl N, Markuszewski L, Owczarek A, Madej P, Chudek J, Olszanecka-GlinianowiczM, (2019) Pentraxin 3 as a marker of endothelial dysfunction in young women with polycystic ovary syndrome (PCOS). Scand J Clin Lab Invest 79(6):419\u2013423. https:\/\/doi.org\/10.1080\/00365513.2019.1637535","journal-title":"Scand J Clin Lab Invest"},{"key":"3461_CR15","doi-asserted-by":"publisher","unstructured":"Notaro\u00a0ALG, Neto FTL (2022) The use of metformin in women with polycystic ovary syndrome: an updated review. J Assist Reprod Genet 39(3):573\u2013579.https:\/\/doi.org\/10.1007\/s10815-022-02429-9","DOI":"10.1007\/s10815-022-02429-9"},{"key":"3461_CR16","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V. Cochrane Handbook for (2022) Systematic reviews of interventions version 6.3 (updated February 2022). Cochrane Available from www.training.cochrane.org\/handbook"},{"issue":"71","key":"3461_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt P et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372(71):1\u20139. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"1","key":"3461_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13643-020-01542-z","volume":"10","author":"L Melissa","year":"2021","unstructured":"Melissa L, Shona Rethlefsen, Siw Kirtley, Patricia Waffenschmidt Ana, David Ayala, Moher Matthew J, Page Jonathan B, Heather Koffel, Tara Blunt, Steven Brigham, Justin Chang, Aislinn Clark, Rachel Conway, Shelley Couban, de Kock Kelly, Farrah Paul, Fehrmann Margaret, Foster Susan A., Fowler Julie, Glanville Elizabeth, Harris Lilian, Hoffecker Jaana, Isojarvi David, Kaunelis Hans, Ket Paul, Levay Jennifer, Lyon Jessie, McGowan M. Hassan, Murad Joey, Nicholson Virginia, Pannabecker Robin, Paynter Rachel, Pinotti Amanda, Ross-White Margaret, Sampson Tracy, Shields Adrienne, Stevens Anthea, Sutton Elizabeth, Weinfurter Kath, Wright Sarah, Young, (2021) PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev 10(1):39. https:\/\/doi.org\/10.1186\/s13643-020-01542-z","journal-title":"Syst Rev"},{"key":"3461_CR19","unstructured":"Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I et al (2022) Technical supplement to chapter 4: searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane Available from: www.training.cochrane.org\/handbook. Accessed 10 Apr 2022"},{"issue":"5","key":"3461_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s1701-2163(16)30402-9","volume":"24","author":"KA Awartani","year":"2002","unstructured":"Awartani KA, Cheung AP (2002) Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can 24(5):393\u2013401. https:\/\/doi.org\/10.1016\/s1701-2163(16)30402-9","journal-title":"J Obstet Gynaecol Can"},{"issue":"5","key":"3461_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-2265.2008.03459.x","volume":"70","author":"M Barba","year":"2009","unstructured":"Barba M, Sch\u00fcnemann HJ, Sperati F et al (2009) The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 70(5):661\u2013670. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03459.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3461_CR22","doi-asserted-by":"publisher","unstructured":"Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ (2015) Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis [published correction appears in Hum Reprod Update. 2016 Apr;22(3):408\u20139]. Hum Reprod Update 21(5):560\u2013574. https:\/\/doi.org\/10.1093\/humupd\/dmv025","DOI":"10.1093\/humupd\/dmv025"},{"issue":"2","key":"3461_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mefs.2014.04.002","volume":"19","author":"S Gill","year":"2014","unstructured":"Gill S, Gemmell A, Colleran R, Zanuri NB, O\u2019Brien H, Poobalan A (2014) Does Metformin combined with clomiphene citrate improve fertility related outcomes in clomiphene resistant women with PCOS: a systematic review. Middle East Fertil Soc J 19(2):81\u201388. https:\/\/doi.org\/10.1016\/j.mefs.2014.04.002","journal-title":"Middle East Fertility Society Journal"},{"issue":"9","key":"3461_CR24","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1080\/03007995.2017.1279597","volume":"33","author":"R Patel","year":"2017","unstructured":"Patel R, Shah G (2017) Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Curr Med Res Opin 33(9):1545\u20131557. https:\/\/doi.org\/10.1080\/03007995.2017.1279597","journal-title":"Curr Med Res Opin"},{"key":"3461_CR25","unstructured":"The Australian National Health and Medical Research Council (NHMRC) (2018) International evidence based guideline for the assessment and management of polycystic ovary syndrome. Available at: https:\/\/www.monash.edu\/__data\/assets\/pdf_file\/0004\/1412644\/PCOS_Evidence-Based-Guidelines_20181009.pdf. Accessed 5 Mar 2022"},{"key":"3461_CR26","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JAC (2022) Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6. (updated February 2022). Cochrane www.training.cochrane.org\/handbook. Accessed Apr 11 2022"},{"key":"3461_CR27","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"3461_CR28","unstructured":"Higgins J et al (2022) Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins J et al (eds)\u00a0Cochrane handbook for systematic reviews of interventions version 6.3. Available from https:\/\/doi.org\/www.training.cochrane.org\/handbook. Accessed 11 Apr\u00a02022"},{"issue":"3","key":"3461_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","volume":"13","author":"C Tufanaru","year":"2015","unstructured":"Tufanaru C, Munn Z, Stephenson M, Aromataris E (2015) Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. Int J Evid Based Health 13(3):196\u2013207. https:\/\/doi.org\/10.1097\/XEB.0000000000000065","journal-title":"Int J Evid Based Health"},{"key":"3461_CR30","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2022) Chapter 10: analysing data and undertaking meta-analyses. In Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds), Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane www.training.cochrane.org\/handbook. Accessed Apr 11 2022"},{"issue":"6","key":"3461_CR31","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jcem-73-6-1294","volume":"73","author":"A Ralph","year":"1991","unstructured":"Ralph A, Defronzo N, Barzilai Simonson DC (1991) Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects*. J Clin Endocrinol Metab 73(6):1294\u20131301. https:\/\/doi.org\/10.1210\/jcem-73-6-1294","journal-title":"J Clin Endocrinol Metab"},{"key":"3461_CR32","unstructured":"Page MJ, Higgins JPT, Sterne JAC (2022) Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds), Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane www.training.cochrane.org\/handbook. Accessed Apr 17 2022"},{"key":"3461_CR33","doi-asserted-by":"publisher","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401\u2013406. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"3461_CR34","unstructured":"Sch\u00fcnemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH (2022) Chapter 14: completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, (eds), Cochrane handbook for systematic reviews of Interventions version 6.3 (updated February 2022). Cochrane. www.training.cochrane.org\/handbook. Accessed Apr 17 2022"},{"key":"3461_CR35","doi-asserted-by":"publisher","unstructured":"Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA (2010) Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab Feb;95(2):722\u201330. https:\/\/doi.org\/10.1210\/jc.2009-1985","DOI":"10.1210\/jc.2009-1985"},{"issue":"5","key":"3461_CR36","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0015-0282(16)58266-1","volume":"65","author":"O A\u00e7bay","year":"1996","unstructured":"A\u00e7bay O, G\u00fcndo\u011fdu S (1996) Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 65(5):946\u2013949","journal-title":"Fertil Steril"},{"issue":"5","key":"3461_CR37","first-page":"465","volume":"10","author":"S Bonakdaran","year":"2012","unstructured":"Bonakdaran S, Mazloom Khorasani Z, Davachi B, Mazloom Khorasani J (2012) The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo- controlled clinical trial. Iran J Reprod Med 10(5):465\u2013472","journal-title":"Iran J Reprod Med"},{"issue":"3","key":"3461_CR38","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1210\/jc.2005-1994","volume":"91","author":"S Eisenhardt","year":"2006","unstructured":"Eisenhardt S, Schwarzmann N, Henschel V et al (2006) Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 91(3):946\u2013952. https:\/\/doi.org\/10.1210\/jc.2005-1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3461_CR39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.fertnstert.2004.02.104","volume":"82","author":"KM Hoeger","year":"2004","unstructured":"Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS (2004) A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and\/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 82(2):421\u2013429. https:\/\/doi.org\/10.1016\/j.fertnstert.2004.02.104","journal-title":"Fertil Steril"},{"issue":"3","key":"3461_CR40","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1210\/jcem.86.3.7295","volume":"86","author":"DJ Jakubowicz","year":"2001","unstructured":"Jakubowicz DJ, Sepp\u00e4l\u00e4 M, Jakubowicz S et al (2001) Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 86(3):1126\u20131133. https:\/\/doi.org\/10.1210\/jcem.86.3.7295","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3461_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/eje.0.1470217","volume":"147","author":"CJ Kelly","year":"2002","unstructured":"Kelly CJ, Gordon D (2002) The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 147(2):217\u2013221. https:\/\/doi.org\/10.1530\/eje.0.1470217","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"3461_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.fertnstert.2007.11.069","volume":"91","author":"SB Kj\u00f8tr\u00f8d","year":"2009","unstructured":"Kj\u00f8tr\u00f8d SB, Sunde A, von D\u00fcring V, Carlsen SM (2009) Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome. Fertil Steril 91(2):500\u2013508. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.11.069","journal-title":"Fertil Steril"},{"issue":"12","key":"3461_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1477-7827-12-98","volume":"11","author":"D Kurzthaler","year":"2014","unstructured":"Kurzthaler D, Hadziomerovic-Pekic D, Wildt L, Seeber BE (2014) Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects. Reprod Biol Endocrinol 11(12):98. https:\/\/doi.org\/10.1186\/1477-7827-12-98","journal-title":"Reprod Biol Endocrinol"},{"issue":"7","key":"3461_CR44","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1471-0528.2006.00966.x","volume":"113","author":"J Lord","year":"2006","unstructured":"Lord J, Thomas R, Fox B, Acharya U, Wilkin T (2006) The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome\u2013a randomised, double-blind, placebo-controlled trial. BJOG 113(7):817\u2013824. https:\/\/doi.org\/10.1111\/j.1471-0528.2006.00966.x","journal-title":"BJOG"},{"issue":"1","key":"3461_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1210\/jcem.85.1.6293","volume":"85","author":"P Moghetti","year":"2000","unstructured":"Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85(1):139\u2013146. https:\/\/doi.org\/10.1210\/jcem.85.1.6293","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3461_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejogrb.2005.05.010","volume":"123","author":"G Onalan","year":"2005","unstructured":"Onalan G, Goktolga U, Ceyhan T, Bagis T, Onalan R, Pabu\u00e7cu R (2005) Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Eur J Obstet Gynecol Reprod Biol 123(2):204\u2013211. https:\/\/doi.org\/10.1016\/j.ejogrb.2005.05.010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"8","key":"3461_CR47","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1210\/jc.2007-0441","volume":"92","author":"S Palomba","year":"2007","unstructured":"Palomba S, Falbo A, Russo T et al (2007) Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 92(8):3128\u20133135. https:\/\/doi.org\/10.1210\/jc.2007-0441","journal-title":"J Clin Endocrinol Metab"},{"key":"3461_CR48","doi-asserted-by":"publisher","unstructured":"Romualdi D, Giuliani M, Cristello F, Fulghesu AM, Selvaggi L, Lanzone A, Guido M (2009) Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Fertil Steril 1;93(7):2303\u201310. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.01.114","DOI":"10.1016\/j.fertnstert.2009.01.114"},{"key":"3461_CR49","doi-asserted-by":"publisher","unstructured":"Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH (2006) Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 21(1):80\u20139. https:\/\/doi.org\/10.1093\/humrep\/dei311","DOI":"10.1093\/humrep\/dei311"},{"issue":"6","key":"3461_CR50","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.fertnstert.2010.01.057","volume":"94","author":"B Trolle","year":"2010","unstructured":"Trolle B, Lauszus FF, Frystyk J, Flyvbjerg A (2010) Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. Fertil Steril 94(6):2234\u20132238. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.01.057","journal-title":"Fertil Steril"},{"issue":"11","key":"3461_CR51","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1093\/humrep\/dem271","volume":"22","author":"B Trolle","year":"2007","unstructured":"Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF (2007) Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 22(11):2967\u20132973. https:\/\/doi.org\/10.1093\/humrep\/dem271","journal-title":"Hum Reprod"},{"issue":"2","key":"3461_CR52","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/humrep\/17.2.289","volume":"17","author":"H Yarali","year":"2002","unstructured":"Yarali H, Yildiz BO, Demirol A, Zeynelo\u011flu HB, Yi\u011fit N, B\u00fck\u00fclmez O, Koray Z (2002) Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 17(2):289\u2013294. https:\/\/doi.org\/10.1093\/humrep\/17.2.289","journal-title":"Hum Reprod"},{"issue":"7414","key":"3461_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"3461_CR54","doi-asserted-by":"publisher","unstructured":"Guan Y, Wang D, Bu H, Zhao T, Wang H (2020) The effect of metformin on polycystic ovary syndrome in overweight women: a systematic review and meta-analysis of randomized controlled trials. Int J Endocrinol 2020:5150684. Published 2020 Sep 16. https:\/\/doi.org\/10.1155\/2020\/5150684","DOI":"10.1155\/2020\/5150684"},{"key":"3461_CR55","doi-asserted-by":"publisher","unstructured":"Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH (2012) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev (5):CD003053. Published 2012 May 16. https:\/\/doi.org\/10.1002\/14651858.CD003053.pub5","DOI":"10.1002\/14651858.CD003053.pub5"},{"key":"3461_CR56","doi-asserted-by":"publisher","unstructured":"Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH (2017) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 11(11):CD003053. https:\/\/doi.org\/10.1002\/14651858.CD003053","DOI":"10.1002\/14651858.CD003053"},{"issue":"1","key":"3461_CR57","doi-asserted-by":"publisher","first-page":"7802","DOI":"10.1038\/s41598-020-64776-w","volume":"10","author":"CH Kim","year":"2020","unstructured":"Kim CH, Chon SJ, Lee SH (2020) Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: a systematic review and meta-analysis. Sci Rep 10(1):7802. https:\/\/doi.org\/10.1038\/s41598-020-64776-w","journal-title":"Sci Rep"},{"issue":"4","key":"3461_CR58","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12291-010-0090-2","volume":"25","author":"B Singh","year":"2010","unstructured":"Singh B, Panda S, Nanda R et al (2010) Effect of metformin on hormonal and biochemical profile in PCOS before and after therapy. Indian J Clin Biochem 25(4):367\u2013370. https:\/\/doi.org\/10.1007\/s12291-010-0090-2","journal-title":"Indian J Clin Biochem"},{"issue":"1","key":"3461_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12958-021-00765-6","volume":"19","author":"M Ohara","year":"2021","unstructured":"Ohara M, Yoshida-Komiya H, Ono-Okutsu M, Yamaguchi-Ito A, Takahashi T, Fujimori K (2021) Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome. Reprod Biol Endocrinol 19(1):77. https:\/\/doi.org\/10.1186\/s12958-021-00765-6","journal-title":"Reprod Biol Endocrinol"},{"issue":"5","key":"3461_CR60","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.fertnstert.2012.07.1057","volume":"98","author":"E Lerchbaum","year":"2012","unstructured":"Lerchbaum E, Schwetz V, Giuliani A, Pieber TR, Obermayer-Pietsch B (2012) Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil Steril 98(5):1318\u201325.e1. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.07.1057","journal-title":"Fertil Steril"},{"issue":"1","key":"3461_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/09513590.2016.1236078","volume":"33","author":"F Fruzzetti","year":"2017","unstructured":"Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A (2017) Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol 33(1):39\u201342. https:\/\/doi.org\/10.1080\/09513590.2016.1236078","journal-title":"Gynecol Endocrinol"},{"key":"3461_CR62","doi-asserted-by":"publisher","unstructured":"Brennan K, Huang A, Azziz R (2009) Dehydroepiandrosterone sulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 91(5):1848\u20131852. https:\/\/doi.org\/10.1016\/j.fertnstert.2008.02.101","DOI":"10.1016\/j.fertnstert.2008.02.101"},{"issue":"1","key":"3461_CR63","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00125-016-4136-8","volume":"60","author":"A Brahimaj","year":"2017","unstructured":"Brahimaj A, Muka T, Kavousi M, Laven JS, Dehghan A, Franco OH (2017) Serum dehydroepiandrosterone levels are associated with lower risk of type 2 diabetes: the Rotterdam study. Diabetologia 60(1):98\u2013106. https:\/\/doi.org\/10.1007\/s00125-016-4136-8","journal-title":"Diabetologia"},{"issue":"3","key":"3461_CR64","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1210\/jcem.78.3.8126125","volume":"78","author":"JE Nestler","year":"1994","unstructured":"Nestler JE, Beer NA, Jakubowicz DJ, Beer RM (1994) Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 78(3):549\u2013554. https:\/\/doi.org\/10.1210\/jcem.78.3.8126125","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3461_CR65","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/s0015-0282(00)00501-x","volume":"73","author":"B Kolodziejczyk","year":"2000","unstructured":"Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L (2000) Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 73(6):1149\u20131154. https:\/\/doi.org\/10.1016\/s0015-0282(00)00501-x","journal-title":"Fertil Steril"},{"issue":"5","key":"3461_CR66","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","volume":"43","author":"EM Velazquez","year":"1994","unstructured":"Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43(5):647\u2013654. https:\/\/doi.org\/10.1016\/0026-0495(94)90209-7","journal-title":"Metabolism"},{"issue":"4","key":"3461_CR67","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/s0015-0282(02)04914-2","volume":"79","author":"R Azziz","year":"2003","unstructured":"Azziz R, Ehrmann DA, Legro RS et al (2003) Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 79(4):932\u2013937. https:\/\/doi.org\/10.1016\/s0015-0282(02)04914-2","journal-title":"Fertil Steril"},{"issue":"5","key":"3461_CR68","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.fertnstert.2005.10.042","volume":"85","author":"O Khorram","year":"2006","unstructured":"Khorram O, Helliwell JP, Katz S, Bonpane CM, Jaramillo L (2006) Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertil Steril 85(5):1448\u20131451. https:\/\/doi.org\/10.1016\/j.fertnstert.2005.10.042","journal-title":"Fertil Steril"},{"issue":"9","key":"3461_CR69","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJM199608293350902","volume":"335","author":"JE Nestler","year":"1996","unstructured":"Nestler JE, Jakubowicz DJ (1996) Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335(9):617\u2013623. https:\/\/doi.org\/10.1056\/NEJM199608293350902","journal-title":"N Engl J Med"},{"issue":"2","key":"3461_CR70","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.rbmo.2019.04.017","volume":"39","author":"Y Han","year":"2019","unstructured":"Han Y, Li Y, He B (2019) GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online 39(2):332\u2013342. https:\/\/doi.org\/10.1016\/j.rbmo.2019.04.017","journal-title":"Reprod Biomed Online"},{"issue":"3","key":"3461_CR71","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1530\/eje.0.1380269","volume":"138","author":"E Diamanti-Kandarakis","year":"1998","unstructured":"Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A (1998) Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138(3):269\u2013274. https:\/\/doi.org\/10.1530\/eje.0.1380269","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"3461_CR72","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1007\/s00125-017-4306-3","volume":"60","author":"S Sam","year":"2017","unstructured":"Sam S, Ehrmann DA (2017) Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia 60(9):1656\u20131661. https:\/\/doi.org\/10.1007\/s00125-017-4306-3","journal-title":"Diabetologia"},{"issue":"4","key":"3461_CR73","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1055\/s-2006-924062","volume":"114","author":"A Mueller","year":"2006","unstructured":"Mueller A, Dittrich R, Cupisti S, Beckmann MW, Binder H (2006) Is it necessary to measure free testosterone to assess hyperandrogenemia in women? The role of calculated free and bioavailable testosterone. Exp Clin Endocrinol Diabetes 114(4):182\u2013187. https:\/\/doi.org\/10.1055\/s-2006-924062","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"3461_CR74","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/jog.14681","volume":"47","author":"L Wang","year":"2021","unstructured":"Wang L, Li J (2021) The value of serum-free androgen index in the diagnosis of polycystic ovary syndrome: a systematic review and meta-analysis. J Obstet Gynaecol Res 47(4):1221\u20131231. https:\/\/doi.org\/10.1111\/jog.14681","journal-title":"J Obstet Gynaecol Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03461-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03461-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03461-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T09:04:25Z","timestamp":1679648665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03461-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3461"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03461-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applied (systematic review).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}